Date: 2013-07-29
Type of information: Grant
Company: Glycovaxyn (Switzerland)
Investors:
Amount: CHF 5.1 million (€ 4.05 million)
Funding type: award
Planned used: The award will allow GlycoVaxyn to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.
Others:
Therapeutic area: Infectious diseases